Allergan, Generic Cos. Battle Over Restasis Launch Plans
By Dani Kass ( October 31, 2018, 10:17 PM EDT) -- Companies hoping to sell generic versions of Allergan's dry-eye medication Restasis have told a New York federal court overseeing multidistrict antitrust litigation that they'll only provide information about their launch dates to the branded-drug maker's outside counsel, but Allergan insists that its in-house attorneys can be trusted....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.